Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer.

Broberg K, Björk J, Paulsson K, Höglund M, Albin M.

Carcinogenesis. 2005 Jul;26(7):1263-71. Epub 2005 Mar 3.

PMID:
15746160
2.

[Individual susceptibility to occupational carcinogens: the evidence from biomonitoring and molecular epidemiology studies].

Pavanello S, Clonfero E.

G Ital Med Lav Ergon. 2004 Oct-Dec;26(4):311-21. Review. Italian.

PMID:
15584438
3.

Cytogenetic biomarkers and genetic polymorphisms.

Norppa H.

Toxicol Lett. 2004 Apr 1;149(1-3):309-34. Review.

PMID:
15093278
4.

Genetic variability in susceptibility and response to toxicants.

Miller MC 3rd, Mohrenweiser HW, Bell DA.

Toxicol Lett. 2001 Mar 31;120(1-3):269-80. Review.

PMID:
11323185
5.

Molecular epidemiology in cancer research.

Collins AR.

Mol Aspects Med. 1998 Dec;19(6):359-432. Review.

PMID:
10385877
6.

Interaction between dose and susceptibility to environmental cancer: a short review.

Hietanen E, Husgafvel-Pursiainen K, Vainio H.

Environ Health Perspect. 1997 Jun;105 Suppl 4:749-54. Review.

7.

Cytogenetic biomarkers.

Norppa H.

IARC Sci Publ. 2004;(157):179-205. Review.

PMID:
15055296
8.

Genetic susceptibility, biomarker respones, and cancer.

Norppa H.

Mutat Res. 2003 Nov;544(2-3):339-48. Review.

PMID:
14644336
9.

Environmental factors promoting bladder cancer.

Hirao Y, Kim WJ, Fujimoto K.

Curr Opin Urol. 2009 Sep;19(5):494-9. doi: 10.1097/MOU.0b013e32832eb4ef. Review.

PMID:
19553820
10.

Heritable susceptibility factors for the development of cancer.

Au WW.

J Radiat Res. 2006;47 Suppl B:B13-7. Review.

11.

Genetic susceptibility to tobacco-related cancer.

Wu X, Zhao H, Suk R, Christiani DC.

Oncogene. 2004 Aug 23;23(38):6500-23. Review.

PMID:
15322521
12.

Smoking and health: association between telomere length and factors impacting on human disease, quality of life and life span in a large population-based cohort under the effect of smoking duration.

Babizhayev MA, Yegorov YE.

Fundam Clin Pharmacol. 2011 Aug;25(4):425-42. doi: 10.1111/j.1472-8206.2010.00866.x. Epub 2010 Aug 4. Review.

PMID:
20698892
13.

Telomere length dynamics in vascular disease: a review.

Butt HZ, Atturu G, London NJ, Sayers RD, Bown MJ.

Eur J Vasc Endovasc Surg. 2010 Jul;40(1):17-26. doi: 10.1016/j.ejvs.2010.04.012. Epub 2010 May 23. Review.

14.

Telomere length heterogeneity and chromosome instability.

Londoño-Vallejo JA.

Cancer Lett. 2004 Aug 30;212(2):135-44. Review.

PMID:
15341022
15.

Walking the telomere plank into cancer.

Wong KK, DePinho RA.

J Natl Cancer Inst. 2003 Aug 20;95(16):1184-6. Review. No abstract available.

PMID:
12928335
16.

Factors contributing to the outcome of oxidative damage to nucleic acids.

Evans MD, Cooke MS.

Bioessays. 2004 May;26(5):533-42. Review.

PMID:
15112233
17.

Telomere length and cardiovascular disease.

Saliques S, Zeller M, Lorin J, Lorgis L, Teyssier JR, Cottin Y, Rochette L, Vergely C.

Arch Cardiovasc Dis. 2010 Aug-Sep;103(8-9):454-9. doi: 10.1016/j.acvd.2010.08.002. Epub 2010 Oct 25. Review.

18.

The emerging role of telomere biology in cardiovascular disease.

Huzen J, de Boer RA, van Veldhuisen DJ, van Gilst WH, van der Harst P.

Front Biosci (Landmark Ed). 2010 Jan 1;15:35-45. Review.

PMID:
20036804
19.

Telomeres and human health.

Bojesen SE.

J Intern Med. 2013 Nov;274(5):399-413. doi: 10.1111/joim.12083. Review.

20.

Supplemental Content

Support Center